alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 10,426–10,450 of 10,985 studies · free to read (page 418 of 440) · 27,380 in the whole library · How the 0–100 score works

Download bibliography of the first 500 of these studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 12,859 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Mapping the impact of age and APOE risk factors for late onset Alzheimer's disease on long range brain connections through multiscale bundle analysis

✓ Peer-reviewed alzhub usefulness score 32 out of 100. Brain structure & function 2025-03-20

Alzheimer's disease currently has no cure and is usually detected too late for interventions to be effective. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

The Role of Medicare Insurance Coverage Type in Annual Wellness Visits: A Comparison between Traditional Medicare and Medicare Advantage Plan

✓ Peer-reviewed alzhub usefulness score 32 out of 100. Alzheimer's & Dementia 2025

Enrollment in an MA plan is associated with a higher probability of AWV uptake, particularly among vulnerable populations from racial and ethnic minorities, dual eligibility, and those diagnosed with ADRD. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Increased Precision in County-Level Volume Estimates in the United States National Forest Inventory With Area-Level Small Area Estimation

✓ Peer-reviewed alzhub usefulness score 32 out of 100. Frontiers in Forests and Global Change 2022-04-26

Many National Forest Inventory (NFI) stakeholders would benefit from accurate estimates at finer geographic scales than most currently implemented in operational estimates using NFI sample data. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

The Amazonian herbal Marapuama attenuates cognitive impairment and neuroglial degeneration in a mouse Alzheimer model

✓ Peer-reviewed alzhub usefulness score 31 out of 100. Phytomedicine : international journal of phytotherapy and phytopharmacology 2010-08-23

This study offers evidence of functional and neuroprotective effects of two weeks treatment with a Ptychopetalum olacoides extract against Aβ peptide-induced neurotoxicity in mice. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Proteomic analysis of host brain components that bind to infectious particles in Creutzfeldt-Jakob disease

✓ Peer-reviewed alzhub usefulness score 31 out of 100. Proteomics 2015-06-09

Transmissible encephalopathies (TSEs), such as Creutzfeldt-Jakob disease (CJD) and scrapie, are caused by infectious agents that provoke strain-specific patterns of disease. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

A nuclear factor-binding domain in the 5'-untranslated region of the amyloid precursor protein promoter: implications for the regulation of gene expression

✓ Peer-reviewed alzhub usefulness score 31 out of 100. BMC research notes 2010-01-12

The 5' untranslated region (UTR) of the APP gene, encompassing 147 base pairs between the transcriptional (+1) and the translational start site, was examined for its role in APP expression. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Production and characterization of a monospecific antiserum (A128) to disaggregated Alzheimer paired helical filaments

✓ Peer-reviewed alzhub usefulness score 31 out of 100. The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society 1990-05-01

Paired helical filaments (PHF), which constitute neurofibrillary tangles (NFT) and neuritic plaque (NP) neurites, serve as a useful marker for Alzheimer disease (AD). 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

HSPA13 gene and microRNA-155: relationship between Down syndrome and Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 31 out of 100. Dementia & neuropsychologia 2025-09-05

Gene dysregulation in trisomy 21 can cause disorders of genes that are members of the heat-shock proteins (HSPs) family and contribute to the early onset of Alzheimer's disease (AD) in Down syndrome (DS). 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

BACH1/HO-1 axis dysregulation links Down syndrome to Alzheimer-like neurodegeneration

✓ Peer-reviewed alzhub usefulness score 31 out of 100. Neurochemistry international 2026-07-30

Down syndrome (DS), caused by trisomy of chromosome 21, is characterized by early-onset oxidative stress, impaired neuronal development, and an increased risk of Alzheimer's disease (AD)-like neuropathology. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Performance on an Everyday Life Activity in Persons Diagnosed with Alcohol Dependency Compared to Healthy Controls: Relations between a Computerized Shopping Task and Cognitive and Clinical Variables†

✓ Peer-reviewed alzhub usefulness score 31 out of 100. Alcohol and Alcoholism 2012-02-20

Performance on the shopping task significantly differentiated patients and healthy controls for several variables and, in particular, for total time. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

3D Team Care Management Trial: Study Design Features and Participant Characteristics

✓ Peer-reviewed alzhub usefulness score 31 out of 100. Innovation in Aging 2020-12-01

This clinical trial was designed in partnership with a Medicare Advantage (MA) plan, with the goal of comparing two care management approaches for its MA policyholders age >65 living with cognitive vulnerability. 5 key findings →

Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

The new paradigm in community-based care: Managing mindset and expectations

✓ Peer-reviewed alzhub usefulness score 31 out of 100. Journal of Emergencies Trauma and Shock 2018-01-01

Some of the considerations that need to be taken into account in coming to a decision include: Disease prevalence and burden in the country The existing health-care model and system The ratio of health-care providers to patient Cost and health-care funding in the country The current and projected health-care demand and needs The perception of the population on FP s and primary care providers versus that of specialists in hospitals and The networks and strengths of the primary care model in the country. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

ACCESS TO HIGH-QUALITY HOME HEALTH CARE FOR PERSONS WITH DEMENTIA

✓ Peer-reviewed alzhub usefulness score 31 out of 100. Innovation in Aging 2024-12-01

Using multiple Medicare Public Use Files (PUF), including star ratings for home health quality of patient care (QoPC), home health care CAHPS survey (HHCAHPS), county-level ADRD prevalence, and Medicare FFS enrollment, we found that the median county-level number of home health agencies was 15 (IQR 8-29), star rating was 3.4 (IQR 3.1-3.7) for QoPC and 3.8 (IQR 3.5-4.0) for HHCAHPS. 2 key findings →

Design: cross-sectional Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled.

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed